D-0641-2020 Class II Ongoing
FDA drug recall D-0641-2020 was initiated by Glenmark Pharmaceuticals Inc., USA on Dec 17, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is ongoing. Affected quantity: 98,988 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 15, 2020
- Initiation Date
- Dec 17, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 98,988 bottles
Product description
Glenmark Ranitidine Tablets USP 300 mg Rx Only 30 Tablets Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale-Bandez, Goa 403513, India Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ NDC 68462-249-30
Reason for recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Distribution pattern
Natiowide
Code information
7701429A 7701522A 7702255A 7704745A 19190456 19190472 19190490
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0641-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026